Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€43.55

€43.55

5.700%
2.35
5.700%
€100.00

€100.00

 
03.05.24 / Tradegate WKN: A1EWVY / Name: Formycon / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
24.03.24
-5.43%
01.12.23
-35.29%
buy
28.10.23
-19.80%
buy
€100.00
25.04.22
-34.90%
buy
Your prediction

Formycon AG Stock

A very strong showing by Formycon AG today, with an increase of €2.35 (5.700%) compared to yesterday's price.
Our community is currently high on Formycon AG with 3 Buy predictions and 1 Sell predictions.
With a target price of 100 € there is potential for a 129.62% increase which would mean more than doubling the current price of 43.55 € for Formycon AG.
Our community identified positive and negative aspects for Formycon AG stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Formycon AG stock. On the other hand our users think that "Valuation (undervalued/overvalued)" could be a problem in the future.

Pros and Cons of Formycon AG in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Formycon AG vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Formycon AG 5.700% 9.560% -4.496% -34.511% -21.953% -33.714% 23.023%
MagForce AG - 25.000% 25.000% 13.636% 212.500% -99.940% -99.947%
Biofrontera AG 6.550% -2.353% 1.220% -71.624% -18.428% -86.504% -95.045%
Medigene AG -0.630% 2.303% -23.399% -8.529% -2.201% -62.165% -82.538%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon initial analysis of Formycon's financial statements, it's evident that this biotechnology and medical research company has seen substantial fluctuations in its financial position over the years. While it may have experienced a few challenges, there are also some notable strengths present in the company's financials. This report aims to provide an in-depth analysis, highlighting both the pros and cons to help potential investors make an informed decision based on Formycon's financial health.

Growing Total Assets: From 2019 to 2021, Formycon has experienced significant growth in its total assets, going from €53,555,323.89 to €66,333,000.00. This uptick is a positive sign, indicating that the company's financial position is improving, and there is potential value generated from its operations.

Reduced Liabilities: The total liabilities of Formycon have shown a decreasing trend, moving from €5,344,603.40 in 2019 to €4,269,670.00 in 2021. A decrease in liabilities is an encouraging sign, suggesting that the company is managing its debt levels effectively.

Comments

Buy Formycon AG
Show more

News

EQS-News: Formycon hosts conference call on the results of the first quarter 2024
EQS-News: Formycon hosts conference call on the results of the first quarter 2024
EQS-News: Formycon hosts conference call on the results of the first quarter 2024
EQS-News: Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
EQS-News: Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
EQS-News: Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
EQS-News: Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
EQS-News: Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
EQS-News: Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024